illumina | GRAIL Illumina Has Acquired GRAIL and Ushered In A New Era of Cancer Detection Illumina has acquired GRAIL for a cash and stock consideration of $8 billion. In addition, GRAIL shareholders will also receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. Illumina will continue to operate GRAIL separately from Illumina’s existing business. This is an exciting moment for both Illumina and GRAIL, and most importantly patients. By re-uniting the two organizations, Illumina and GRAIL will accelerate the global adoption of NGS-based multi-cancer early detection tests, increase accessibility, and improve patient outcomes. Cancer kills around 10 million people annually worldwide and 600,000 people in the United States alone. Survival rates are higher when cancer is detected early. Seventy-one percent of all deadly cancers do not currently have a screening test. GRAIL’s Galleri test is able to detect more than 50 cancers across all stages, more than 45 of which do not have recommended screening in the United States. And, in 89 percent of the positive results, the test correctly identified the tissue of origin – all with a specificity of 99.5 percent. LATEST PRESS RELEASE FACT SHEET STANDARD CONTRACT FOR US ONCOLOGY CUSTOMERS Detecting Cancer Early, When it Can be Cured 71% of cancer-related deaths are in cancers with no recommended screening Source: SEER Program (www.seer.cancer.gov) *Stat Database: Incidence – SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015 “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body. Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018. Beating Cancer Starts with Finding It Introducing GalleriTM 1 Based on current trial status In 2021, GRAIL published positive results from its Circulating Cell-free Genome Atlas (CCGA) study that enrolled more than 15,000 participants. The study found that Galleri reported sensitivity of 16.8%, 40.4% and 77.0% for stage I-III tumors, respectively, and 67.6% stage I-III sensitivity for the 12 deadliest cancers that account for approximately two-thirds of annual USA cancer deaths and 40.7% stage I-III sensitivity in all cancers. Further, Galleri was able to detect over 50 types of cancers across all stages, more than 45 of which do not have recommended screening in the US. And in 88.7% of the positive results, the test correctly identified the cancer signal of origin, or where the cancer originated from in the body – all with a low false positivity rate of less than 1%. Galleri was introduced in 2021 as a laboratory developed test for early cancer detection. Galleri, which requires a prescription, is available initially through partner health systems, medical practices, and self-insured employers. Meets Patient, Physician & Payor Needs Improves Outcomes Today, 71% of cancer-related deaths are in cancers with no recommended screening. With limited screening, cancer is more likely to be detected in late stages but when we diagnose cancer too late, less than 20% of patients will survive more than 5 years. In contrast, if we diagnose cancer early, approximately 90% of patients are expected to survive beyond five years.3 Up to 65% Reduction in Cost Galleri has the potential to more efficiently identify cancers and reduce overall diagnostic workup costs.4 We estimate that ~44% of patients who are tested positive will have cancer. This represents a very significant step forward compared to today’s most commonly used screening tests, which often have a positive predictive value in the 3 to 5% range. 1 Clarke et al. Cancer Epidemiology, Biomarkers, & Prevention 2020 2 Modeled based on GRAIL’s recent data from ESMO 2019 and SEER cancer registry 3 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) 4 Diagnostic workup cost estimates include downstream costs + initial screening test Illumina Will Continue to Enable, Partner and Supply Customers ILLUMINA Contacts Investors: Brian Blanchett IR@illumina.com 858.291.6421 Media: Dr. Karen Birmingham pr@illumina.com 646-355-2111 +44 7500 105665